# Senomorphic Activity of a Novel Standardized Propolis Extract in Human Dermal Fibroblasts: Molecular Insights Into Clinically Proven Anti‐Wrinkle Efficacy

## TL;DR

A new propolis extract reduces wrinkles by targeting aging-related inflammation in skin cells, offering a scientifically backed anti-aging treatment.

## Contribution

This is the first study to demonstrate senomorphic activity of a standardized propolis extract, linking its anti-wrinkle effects to SASP suppression and cell cycle modulation.

## Key findings

- The propolis extract significantly reduced the SASP marker IL-6 in senescent fibroblasts.
- The extract uniquely upregulated CDK4 and CDKN1A/p21, suggesting pro-regenerative effects.
- Qualitative reduction in SA-β-galactosidase activity in mesenchymal stem cells was observed.

## Abstract

We recently demonstrated in a randomized controlled trial (RCT) that a Standardized Propolis Extract (SPE), produced via a patented non‐alcoholic PEG 400/lecithin process, achieves significant clinical anti‐wrinkle efficacy (34% wrinkle depth reduction). The present study investigates the underlying molecular mechanisms, specifically its potential senomorphic activity—the ability to modulate the Senescence‐Associated Secretory Phenotype (SASP) without inducing cell death.

To evaluate the senomorphic activity of this chemically defined SPE (standardized to 1318.43 μg/g total phenolic markers) in an in vitro model of oxidative stress‐induced senescence, providing molecular insights into its clinically observed anti‐aging effects.

Human Dermal Fibroblasts (HDFs) were pre‐treated with SPE (0.01%, 0.05%) or Rapamycin (3 μM, reference senomorphic control). Senescence was induced via a validated stress‐induced premature senescence (SIPS) protocol (200 μM H2O2, 2 h). Gene expression for senescence markers (CDKN2A/p16, CDKN1A/p21), SASP cytokines (IL‐6, IL‐8), and cell cycle regulators (CDK4, CDK2, CCNE1) was quantified by qPCR. An exploratory study on Mesenchymal Stem Cells (MSCs) assessed SA‐β‐galactosidase activity qualitatively.

The 0.05% SPE demonstrated potent senomorphic activity, significantly suppressing the key SASP marker IL‐6 (FC: −7.78, p = 0.003)—comparable to the Rapamycin control (FC: −8.1, p = 0.003). Uniquely, SPE induced transcriptional upregulation of CDK4 (FC: +6.71, p = 0.002) and CDKN1A/p21 (FC: +2.33, p = 0.005), effects not observed with Rapamycin. In exploratory MSC experiments, SPE qualitatively reduced SA‐β‐gal staining.

This first‐in‐class standardized propolis extract demonstrates distinct senomorphic activity, suppressing the inflammatory SASP (IL‐6) while inducing transcriptional modulation of pro‐regenerative pathways (CDK4). These molecular findings provide mechanistic insights consistent with the extract's clinically proven anti‐wrinkle efficacy, supporting its positioning as an evidence‐based active ingredient for dermo‐cosmetic formulations targeting inflammaging.